SHILPAMED Shilpa Medicare Ltd Product Launches Announcement 2024 - FDA NDA Acceptance Shilpa Medicare Limited announced that the US FDA has accepted the New Drug Application for Oxylanthanum Carbonate (OLC) filed by its partner Unicycive, targeting a decision by June 28, 2025, which may enhance treatment for kidney disease patients. Shilpa will supply the product commercially if approved, expected to launch in late 2025..Find Corporate Announcements for Press Releases, AGM, Insider Trading & SAST, Results and Corporate Action for Shilpa Medicare Ltd